MedLumics, SL

MedLumics, founded in 2009, is at the forefront of revolutionizing cardiac care with our pioneering biophotonics technology. Initially focusing on dermatological applications, we shifted our trajectory towards cardiac health in 2014, identifying a crucial gap in real-time heart tissue visualization during ablation procedures. This led to the development of the AblaView® Unipolar Hybrid System, an innovative solution designed to enhance the precision and safety of cardiac ablations, specifically targeting the treatment of atrial fibrillation. Our mission is to enlighten healthcare by delivering high-quality, innovative medical products that significantly improve global healthcare standards. We envision AblaView® becoming an indispensable tool in cardiac ablation treatments worldwide, aiming to improve patient outcomes, reduce procedure recurrence rates, and achieve greater efficiency and cost-effectiveness in healthcare systems. With a rich patent portfolio and state-of-the-art laboratory facilities in Madrid, MedLumics has developed a complete system around the AblaView®. We benefit from a strong network of industrial, scientific, and clinical partners, along with a world-class scientific advisory board, contributing to our research development and strategic direction. Our long-term ambition extends beyond AF to other cardiac catheter uses and medical areas, as well as integrating AI into our technology to further advance healthcare solutions. 

Atrial fibrillation (AF), the most common heart rhythm disorder, affects 43 million people globally, leading to severe complications like heart failure and stroke. Current pharmacological treatments often fail to prevent recurrences and may have significant side effects. Catheter ablation emerges as a promising solution, offering a minimally invasive approach with curative potential, now recommended as a first-line therapy. However, its efficacy is limited by technological drawbacks such as inadequate real-time tissue visualization and lesion assessment and complex equipment, compromising patient outcomes. Electrophysiologists face these issues directly, struggling with ablation catheters that lack tissue visualization, flexibility, and the ability to provide immediate feedback on procedural efficacy. To address this need, MedLumics is developing AblaView® Unipolar Hybrid System, a first-in-class catheter system for image-guided hybrid ablation therapy. The system integrates radiofrequency (RF ablation; the current state-of-the-art) and pulsed field (PF ablation; emerging and innovative) energy delivery with cutting-edge, real-time tissue imaging using polarization-sensitive optical coherence reflectometry (PS-OCR). This allows for unprecedented direct monitoring of tissue contact, stability, and lesion formation during both RF and PFA procedures, and precise post-ablation gap assessment to ensure lesion continuity. The AblaView® system's optical technology offers real-time insights into tissue changes below the endocardial surface. MedLumics' proprietary algorithms utilize these insights to predict lesion depth and the risk of complications, providing unique, direct procedural feedback not available with other ablation technology on the market today. Offering both RF and PF energy flexibility as well as optically guided precision & real-time lesion assessment, AblaView® is set to significantly improve procedural accuracy, reduce AF recurrence rates, procedure times, and healthcare costs, and has the potential to benefit other arrhythmias and cardiac conditions.